Pages that link to "Q73731609"

The following pages link to Safety Profile of Phase I and II Preventive HIV Type 1 Envelope Vaccination: Experience of the NIAID AIDS Vaccine Evaluation Group (Q73731609):

Displaying 31 items.

• Obstacles to the successful development of an efficacious T cell-inducing HIV-1 vaccine. (Q30378897) (← links)
• Serum cytokine profiles associated with specific adjuvants used in a DNA prime-protein boost vaccination strategy (Q31138173) (← links)
• HIV vaccines. (Q33591503) (← links)
• Assessment of HIV vaccine development: past, present, and future (Q34050712) (← links)
• Recent developments in adjuvants for vaccines against infectious diseases (Q34376294) (← links)
• The development and use of vaccine adjuvants (Q34680503) (← links)
• HIV-1 vaccines: the search continues (Q34876150) (← links)
• Meta-Analysis on Randomized Controlled Trials of Vaccines with QS-21 or ISCOMATRIX Adjuvant: Safety and Tolerability (Q36009558) (← links)
• HIV Vaccine Trials Network: activities and achievements of the first decade and beyond (Q36464748) (← links)
• The safety and tolerability of an HIV-1 DNA prime-protein boost vaccine (DP6-001) in healthy adult volunteers (Q36945335) (← links)
• Immunotherapies to prevent mother-to-child transmission of HIV (Q37316629) (← links)
• Modulation of HIV-1 immunity by adjuvants (Q37698564) (← links)
• The first generation of candidate HIV-1 vaccines can induce antibodies able to neutralize primary isolates in assays with extended incubation phases (Q38976321) (← links)
• A phase I trial in HIV negative healthy volunteers evaluating the effect of potent adjuvants on immunogenicity of a recombinant gp120W61D derived from dual tropic R5X4 HIV-1ACH320. (Q39232080) (← links)
• Long-term memory B-cell responses in recipients of candidate human immunodeficiency virus type 1 vaccines (Q40546496) (← links)
• Three double-blind, randomized trials evaluating the safety and tolerance of different formulations of the saponin adjuvant QS-21. (Q43654252) (← links)
• Comparative immunomodulatory properties of a chitosan-MDP adjuvant combination following intranasal or intramuscular immunisation (Q43769664) (← links)
• Relationship between haemolytic and adjuvant activity and structure of protopanaxadiol-type saponins from the roots of Panax notoginseng (Q46663461) (← links)
• Safety profile of recombinant canarypox HIV vaccines (Q47245576) (← links)
• Long-term safety analysis of preventive HIV-1 vaccines evaluated in AIDS vaccine evaluation group NIAID-sponsored Phase I and II clinical trials (Q47845658) (← links)
• Immunological adjuvant effect of Glycyrrhiza uralensis saponins on the immune responses to ovalbumin in mice (Q50748929) (← links)
• Haemolytic activities and adjuvant effect of Astragalus membranaceus saponins (AMS) on the immune responses to ovalbumin in mice (Q50759965) (← links)
• Why blacks do not take part in HIV vaccine trials. (Q50905628) (← links)
• Pulcherrimasaponin, from the leaves of Calliandra pulcherrima, as adjuvant for immunization in the murine model of visceral leishmaniasis. (Q51820796) (← links)
• Novel alleles at the lymphotoxin alpha (LTalpha) locus mark extended HLA haplotypes in native Africans (Q52542558) (← links)
• Multi-envelope HIV vaccine safety and immunogenicity in small animals and chimpanzees. (Q52844350) (← links)
• QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immmunization in humans (Q56447939) (← links)
• Stakeholder engagement to inform HIV clinical trials: a systematic review of the evidence (Q58595713) (← links)
• A phase I/II trial of HIV SF2 gp120/MF59 vaccine in seronegative Thais (Q59309192) (← links)
• Bridging the divide: HIV prevention research and Black men who have sex with men (Q64110655) (← links)
• Saponins, IL12 and BCG adjuvant in the FML-vaccine formulation against murine visceral leishmaniasis (Q78550077) (← links)